Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants

被引：2
|
作者：
Zubkov, Micaella R. [1 ]
Waldman, Reid A. [2 ]
Wu, Rong [4 ]
Grant-Kels, Jane M. [2 ,3 ]
机构：
[1] Univ Connecticut Sch Med, Farmington, CT USA
[2] Univ Connecticut Hlth Ctr, Dept Dermatol, Farmington, CT 06030 USA
[3] Univ Florida, Dept Dermatol, Gainesville, FL USA
[4] Univ Connecticut, Connecticut Convergence Inst Translat Regenerat E, Farmington, CT USA
来源：
CUTIS | 2021年 / 108卷 / 04期
关键词：
D O I：
10.12788/cutis.0366
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：199 / 200
页数：2
相关论文
共 50 条
  • [31] Successful desensitization with adalimumab in a patient with hidradenitis suppurativa
    Foncubierta Fernandez, A.
    Gutierrez Fernandez, D.
    Cruz Carmona, M. J.
    Moreno Ancillo, A.
    Anguita Carazo, J. L.
    Fernandez Anguita, M. J.
    ALLERGY, 2015, 70 : 552 - 552
  • [32] A Presentation of Neisseria meningitidis in a Patient Taking Adalimumab as Immunosuppressive Therapy for Hidradenitis Suppurativa
    Bolling, Jacob W.
    Holley, Aaron D.
    Rogers, Cleon
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (09)
  • [33] IgA Vasculitis With Adalimumab Therapy for Hidradenitis Suppurativa: A Case Report and Review of Literature
    Alsulami, Sarah
    Alotaibi, Rakan M.
    Alotaibi, Faisal F.
    Almatrafi, Faisal B.
    Filmban, Doaa M.
    Alneefia, Sultan
    Alahmed, AhmedHusam
    Hafiz, Waleed A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [34] Hyperbaric oxygen therapy (HBOT) can improve the effectiveness of adalimumab in hidradenitis suppurativa
    Marasca, Claudio
    Vivona, Giovanni
    Annunziata, Maria Carmela
    Cacciapuoti, Sara
    Capasso, Emilia
    Ciotola, Alessandra
    Russo, Gianmarco
    Fabbrocini, Gabriella
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2020, 155 (02): : 234 - 235
  • [35] Steatocystoma multiplex suppurativa associated with hidradenitis suppurativa successfully treated with adalimumab
    Atzori, L.
    Zanniello, R.
    Pilloni, L.
    Rongioletti, F.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 42 - 44
  • [36] NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram, J. R.
    Burton, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (02) : 281 - 282
  • [37] Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa
    Das, Kinnor
    Daveluy, Steven
    Kroumpouzos, George
    Agarwal, Komal
    Podder, Indrashis
    Farnbach, Katherine
    Ortega-Loayza, Alex G.
    Szepietowski, Jacek C.
    Grabbe, Stephan
    Goldust, Mohamad
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (03)
  • [38] A novel hidradenitis suppurativa efficacy variable, HiSCR (hidradenitis suppurativa clinical response), is responsive to change with adalimumab therapy: Results of a phase II study
    Kimball, Alexandra B.
    Williams, David A.
    Jemec, Gregor B. E.
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB40 - AB40
  • [39] Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa
    Al-Tkrit, Amna
    Obada, Zaid
    Muqeet, Sara
    Cervantes, Jose
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [40] Adalimumab-Induced Neutropenia in a Man With Hidradenitis Suppurativa
    Rueda Carnero, J. M.
    Nieto Rodriguez, D.
    de Lucas Laguna, R.
    Feito Rodriguez, M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2020, 111 (03): : 273 - 274
12345